nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—AVPR2—nephron—focal segmental glomerulosclerosis	0.475	0.697	CbGeAlD
Conivaptan—AVPR2—nephron tubule—focal segmental glomerulosclerosis	0.103	0.15	CbGeAlD
Conivaptan—AVPR2—kidney—focal segmental glomerulosclerosis	0.0901	0.132	CbGeAlD
Conivaptan—CYP3A4—kidney—focal segmental glomerulosclerosis	0.0137	0.0201	CbGeAlD
Conivaptan—AVPR2—Arf6 trafficking events—AGTR1—focal segmental glomerulosclerosis	0.0131	0.0549	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.0119	0.05	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.0118	0.0497	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00917	0.0385	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00911	0.0382	CbGpPWpGaD
Conivaptan—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0066	0.082	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00571	0.024	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00561	0.0235	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00557	0.0234	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00511	0.0214	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00478	0.02	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00439	0.0184	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00437	0.0183	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00436	0.0183	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00431	0.0181	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00428	0.018	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00427	0.0179	CbGpPWpGaD
Conivaptan—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.004	0.0497	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00391	0.0164	CbGpPWpGaD
Conivaptan—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00379	0.0471	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00376	0.0158	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00374	0.0157	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.0037	0.0155	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00366	0.0153	CbGpPWpGaD
Conivaptan—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00364	0.0452	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00363	0.0152	CbGpPWpGaD
Conivaptan—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00346	0.0431	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00338	0.0142	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00335	0.0141	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00331	0.0139	CbGpPWpGaD
Conivaptan—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00312	0.0388	CcSEcCtD
Conivaptan—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00312	0.0388	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00307	0.0129	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00304	0.0127	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00301	0.0126	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00289	0.0121	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00287	0.012	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00287	0.012	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00284	0.0119	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.00275	0.0115	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00245	0.0103	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00244	0.0102	CbGpPWpGaD
Conivaptan—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00243	0.0302	CcSEcCtD
Conivaptan—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.0295	CcSEcCtD
Conivaptan—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00236	0.0293	CcSEcCtD
Conivaptan—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00234	0.0291	CcSEcCtD
Conivaptan—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00234	0.0291	CcSEcCtD
Conivaptan—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00228	0.0283	CcSEcCtD
Conivaptan—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.0278	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.00221	0.00929	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.0022	0.00924	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00219	0.00918	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.0258	CcSEcCtD
Conivaptan—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00206	0.0256	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00204	0.00854	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00202	0.00848	CbGpPWpGaD
Conivaptan—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.0237	CcSEcCtD
Conivaptan—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.0236	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00187	0.00784	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00185	0.00778	CbGpPWpGaD
Conivaptan—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00184	0.0229	CcSEcCtD
Conivaptan—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00183	0.0228	CcSEcCtD
Conivaptan—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.021	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00163	0.00683	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00162	0.00679	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00162	0.00678	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00161	0.00674	CbGpPWpGaD
Conivaptan—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.0197	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00155	0.0065	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.0193	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00154	0.00646	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00153	0.00642	CbGpPWpGaD
Conivaptan—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.019	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00152	0.00637	CbGpPWpGaD
Conivaptan—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00151	0.0187	CcSEcCtD
Conivaptan—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.0185	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00148	0.0062	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00147	0.00617	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00147	0.00616	CbGpPWpGaD
Conivaptan—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.0182	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00146	0.00612	CbGpPWpGaD
Conivaptan—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00145	0.0181	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00141	0.0059	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.0014	0.00586	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00136	0.00571	CbGpPWpGaD
Conivaptan—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.0168	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00135	0.00567	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.016	CcSEcCtD
Conivaptan—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0159	CcSEcCtD
Conivaptan—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0159	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00125	0.00522	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.00124	0.00519	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00124	0.00519	CbGpPWpGaD
Conivaptan—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.0153	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.00123	0.00515	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.00119	0.00498	CbGpPWpGaD
Conivaptan—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.0147	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.00118	0.00495	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00113	0.00474	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00112	0.00471	CbGpPWpGaD
Conivaptan—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.0132	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00106	0.00443	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00105	0.0044	CbGpPWpGaD
Conivaptan—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.0127	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000959	0.00402	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000952	0.00399	CbGpPWpGaD
Conivaptan—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000951	0.0118	CcSEcCtD
Conivaptan—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000937	0.0116	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000914	0.00384	CbGpPWpGaD
Conivaptan—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000888	0.011	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000876	0.00368	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000874	0.00366	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.00087	0.00365	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000869	0.00364	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000867	0.00364	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000862	0.00362	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000796	0.00334	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.00079	0.00331	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00073	0.00306	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000725	0.00304	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000668	0.0028	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000663	0.00278	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000566	0.00238	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000562	0.00236	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000549	0.0023	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000546	0.00229	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00052	0.00218	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000517	0.00217	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.00047	0.00197	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000467	0.00196	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000434	0.00182	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000431	0.00181	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000361	0.00152	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000359	0.0015	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000277	0.00116	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000275	0.00115	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000228	0.000957	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000227	0.00095	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000125	0.000526	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	0.00011	0.000463	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000102	0.000427	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	7.66e-05	0.000321	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	6.55e-05	0.000275	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	5.03e-05	0.000211	CbGpPWpGaD
